Dr. Weisman has been interviewed in a new article in Neurology Insights regarding the unique challenges faced by Alzheimer’s patients and caregivers during the pandemic.
Your health is our top priority and we want to ensure that you are accessing — and not delaying — the care you need.
In many ways we’ve been fortunate. Despite a pandemic, society has not broken down.
The field of epilepsy has seen great strides in the last couple of decades.
Aducanumab, the first Alzheimer’s-modifying therapy, submitted to the FDA. Can Biogen recover from their errors?
“If you have a loved one with dementia, you know this can be a heart-wrenching process. You cannot change the person. . . . You have to meet them where they are, roll with it, and speak with love and patience. It was a pleasure to speak to Dr. David Weisman, a neurologist.”
The field of MS research has had amazing success in the last two decades.
Multiple sclerosis (MS) is an autoimmune disease in which the immune system misrecognizes part of the brain called myelin.
Early on in their careers, two neurologists became involved in advocacy issues on behalf of neurology on a national, regional, and local level.
One day, one of the trials in Alzheimer’s disease will be positive. We think this trial may already be underway.